Antimicrobial Resistance Surveillance Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services), By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications), By End User (Hospitals & Clinics, Research & Academic Institutes, Others), By Region, and By Competition, 2019-2029F
Global Antimicrobial Resistance Surveillance Market was valued at USD 5.97 billion in 2023 and will see an impressive growth in the forecast period at a CAGR of 5.88% tthrough 2029. Antimicrobial Resistance Surveillance is a structured method used to monitor the prevalence, trends, and patterns of antimicrobial resistance (AMR) across different populations and environments. Its main goal is to track the emergence and spread of drug-resistant pathogens, evaluate the impact of antimicrobial use on resistance development, and guide evidence-based strategies for antimicrobial stewardship and infection control. Surveillance systems collect data from antimicrobial susceptibility testing (AST) conducted on clinical specimens such as blood, urine, respiratory secretions, and wound swabs. AST assesses the susceptibility of microbial isolates to specific antimicrobial agents, including antibiotics, antivirals, antifungals, and antiparasitic drugs, using methods like disk diffusion, broth microdilution, agar dilution, and molecular assays.
Testing procedures are governed by standardized protocols and interpretive criteria established by clinical and laboratory standards organizations. Analysis of surveillance data reveals trends in antimicrobial resistance, including changes over time, regional differences, and variations across patient demographics and healthcare settings. Surveillance networks facilitate data sharing, collaboration, and information exchange among healthcare facilities, public health agencies, research institutions, and international organizations. They promote methodological standardization, consistent data reporting, and coordinated responses to combat antimicrobial resistance globally.
Advancements in diagnostic technologies such as molecular diagnostics, next-generation sequencing, and rapid point-of-care testing have transformed antimicrobial resistance surveillance, enabling rapid detection, characterization, and monitoring of drug-resistant pathogens. Antimicrobial stewardship programs have become increasingly important in healthcare facilities to encourage prudent antibiotic use and mitigate the spread of resistant infections. With globalization facilitating the rapid spread of drug-resistant strains, surveillance systems are crucial for monitoring resistance trends, detecting outbreaks, and implementing infection control measures to prevent international transmission.
Key Market Drivers
Technological Advancements in Surveillance Tools
NGS technologies enable rapid and high-throughput sequencing of microbial genomes, facilitating the identification of genetic mutations associated with antimicrobial resistance. NGS allows researchers to analyze entire microbial populations and track the spread of resistant strains with high precision. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), enable the rapid detection of specific genetic markers associated with antimicrobial resistance. These techniques provide accurate and timely information about resistance profiles, guiding treatment decisions and infection control measures. Bioinformatics tools and data analytics platforms enable the analysis and interpretation of large-scale genomic data generated by surveillance efforts. Advanced algorithms and computational techniques facilitate the identification of resistance patterns, genetic determinants, and evolutionary pathways of drug-resistant pathogens. Point-of-Care Testing (POCT) devices allow for rapid and on-site detection of antimicrobial resistance in clinical settings, enabling timely treatment decisions and reducing the spread of drug-resistant infections. POCT technologies leverage miniaturized platforms, microfluidics, and integrated sensors to provide real-time results with minimal sample processing.
Whole Genome Sequencing (WGS) technologies provide comprehensive insights into the genetic composition of microbial populations, including antimicrobial resistance genes, virulence factors, and genomic variations. WGS enables detailed molecular characterization of pathogens and facilitates epidemiological investigations, outbreak detection, and surveillance of resistance trends. Mass spectrometry-based methods, such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, enable rapid and accurate identification of microbial species and determination of antimicrobial susceptibility profiles. Mass spectrometry platforms offer high throughput and multiplexing capabilities, making them suitable for large-scale surveillance studies. Biosensors and microfluidic devices enable the detection of antimicrobial resistance markers in complex biological samples with high sensitivity and specificity. These miniaturized platforms integrate sensing elements, microfluidic channels, and signal processing components to provide rapid and portable solutions for surveillance applications. This factor will help in the development of the Global Antimicrobial Resistance Surveillance Market.
Growing Need for Antimicrobial Stewardship Programs
Antimicrobial stewardship programs are essential in combating the rising threat of antimicrobial resistance. Surveillance of antimicrobial resistance patterns provides critical data that informs ASPs about the prevalence and trends of resistant pathogens, enabling healthcare facilities to implement targeted interventions to optimize antibiotic use and prevent the spread of resistant infections. Antimicrobial stewardship programs aim to promote judicious and appropriate use of antibiotics to preserve their effectiveness and minimize the development of resistance. Surveillance data helps ASPs monitor antibiotic prescribing practices, identify areas of overuse or misuse, and implement strategies to improve antibiotic prescribing behaviors among healthcare providers. Antimicrobial resistance surveillance data informs empirical therapy guidelines and treatment algorithms by providing insights into local resistance patterns and susceptibility profiles of common pathogens. ASPs use surveillance data to guide the selection of appropriate antibiotics for initial empiric therapy, reducing the risk of treatment failure and the emergence of resistance.
Surveillance of antimicrobial resistance facilitates early detection of outbreaks and emerging resistance trends within healthcare settings and communities. ASPs rely on surveillance data to identify clusters of resistant infections, investigate potential sources of transmission, and implement infection control measures to contain the spread of resistant pathogens. Antimicrobial stewardship programs continuously evaluate the impact of interventions on antibiotic prescribing practices and antimicrobial resistance patterns. Surveillance data allows ASPs to assess the effectiveness of stewardship initiatives, monitor changes in resistance trends over time, and adjust strategies as needed to optimize patient outcomes and minimize the spread of resistance. Many regulatory agencies and accreditation bodies require healthcare facilities to implement antimicrobial stewardship programs as part of efforts to address antimicrobial resistance. Compliance with regulatory requirements necessitates the implementation of robust surveillance systems to monitor antimicrobial use and resistance patterns, driving demand for surveillance solutions in the market. This factor will pace up the demand of the Global Antimicrobial Resistance Surveillance Market.
Emerging Infectious Diseases and Pandemics
During outbreaks of emerging infectious diseases or pandemics, there is often a surge in antibiotic use, both for treating bacterial co-infections and as a precautionary measure. This overuse of antibiotics can contribute to the development and spread of antimicrobial resistance among pathogens, exacerbating the AMR crisis. Emerging infectious diseases and pandemics can complicate treatment protocols by introducing new pathogens or strains with unique resistance profiles. Surveillance of antimicrobial resistance patterns becomes essential for understanding the susceptibility of these pathogens to available antibiotics and guiding treatment decisions. Antimicrobial resistance surveillance helps in the early detection of drug-resistant strains of pathogens associated with emerging infectious diseases and pandemics. Timely identification of resistant strains enables healthcare authorities to implement appropriate infection control measures, prevent further transmission, and optimize treatment strategies to improve patient outcomes.
Surveillance of antimicrobial resistance provides valuable data on the dynamics of resistance development and spread during outbreaks and pandemics. Understanding the patterns of resistance evolution helps public health agencies and healthcare providers anticipate future challenges, adapt treatment protocols, and develop targeted interventions to mitigate the impact of AMR. Effective surveillance of antimicrobial resistance is crucial for preserving the efficacy of antibiotics and other antimicrobial agents used to treat both common and emerging infectious diseases. By monitoring resistance trends and patterns, healthcare systems can implement antimicrobial stewardship programs and infection prevention measures to minimize the selective pressure driving resistance evolution. Emerging infectious diseases and pandemics require coordinated global efforts to monitor, control, and mitigate their impact. Antimicrobial resistance surveillance fosters collaboration among countries, international organizations, and research institutions to share data, resources, and best practices for responding to public health emergencies effectively. This factor will accelerate the demand of the Global Antimicrobial Resistance Surveillance Market.
Key Market Challenges
Rapidly Evolving Resistance Patterns
Pathogens can develop resistance to antimicrobial agents through various mechanisms, including genetic mutations, horizontal gene transfer, and the acquisition of mobile genetic elements. The diverse and evolving nature of resistance mechanisms makes it challenging to predict and track changes in resistance patterns accurately. New and unexpected resistance mechanisms can emerge over time, rendering existing surveillance methods and assays ineffective in detecting and characterizing resistant strains. The identification of novel resistance mechanisms requires continuous research and development efforts to update surveillance tools and technologies accordingly. Drug-resistant pathogens can spread rapidly within and across healthcare settings, communities, and geographic regions. The global dissemination of resistant strains complicates surveillance efforts and necessitates international collaboration and data sharing to monitor resistance trends and prevent the spread of resistant infections. The selective pressure exerted by the widespread use and misuse of antibiotics accelerates the development and spread of antimicrobial resistance. Antibiotic exposure drives the selection of resistant bacterial populations, leading to the emergence of multidrug-resistant strains that are difficult to treat and control. Pathogens have the capacity to adapt and evolve in response to environmental pressures, including exposure to antimicrobial agents. The adaptive evolution of pathogens allows them to develop mechanisms to evade the effects of antibiotics, leading to the persistence and proliferation of resistant strains in clinical and community settings. Resistance patterns can vary widely among different pathogens, patient populations, and geographic locations. The heterogeneity of resistance patterns presents challenges in standardizing surveillance methods, interpreting surveillance data, and implementing targeted interventions to address specific resistance threats effectively.
Lack of Standardization
There is a lack of standardized protocols and methodologies for data collection, analysis, and reporting across different regions, healthcare settings, and surveillance programs. This inconsistency makes it difficult to compare and interpret surveillance data accurately, hindering efforts to monitor antimicrobial resistance trends on a global scale. Variability in testing procedures, including antimicrobial susceptibility testing methods, interpretive criteria, and quality control measures, can lead to discrepancies in resistance data reported by different laboratories and surveillance systems. Without standardized testing protocols, the reliability and comparability of surveillance data are compromised. Surveillance infrastructure varies widely among countries and healthcare systems, resulting in disparities in surveillance capabilities and data quality. Resource-limited settings may lack the necessary laboratory facilities, trained personnel, and data management systems to conduct robust antimicrobial resistance surveillance effectively. The lack of standardized data formats, interoperable systems, and secure platforms for data sharing and integration hinders collaboration and information exchange among stakeholders involved in antimicrobial resistance surveillance. Fragmented data silos impede efforts to track resistance trends, identify emerging threats, and coordinate response strategies across borders and sectors. Differences in definitions, terminologies, and classification schemes used to describe antimicrobial resistance phenotypes and resistance mechanisms can lead to confusion and misinterpretation of surveillance data. Harmonizing terminology and standardizing nomenclature are essential for ensuring consistency and accuracy in resistance surveillance reporting.
Key Market Trends
Point-of-Care Testing (POCT) Solutions
Point-of-care testing (POCT) solutions facilitate swift and on-site detection of antimicrobial resistance in clinical environments, enabling healthcare providers to promptly determine treatment courses. This rapid access to test results expedites the commencement of appropriate antibiotic therapy, leading to enhanced patient outcomes and reduced spread of drug-resistant infections. Unlike conventional laboratory-based antimicrobial susceptibility testing (AST) methods, which often involve lengthy turnaround times, POCT solutions offer near-real-time results, minimizing delays in diagnosis and allowing healthcare providers to promptly select the most effective antibiotics.
POCT solutions support personalized and precision medicine approaches by furnishing actionable insights into antimicrobial resistance patterns and susceptibility profiles. This empowers healthcare providers to customize antibiotic therapy based on individual patient characteristics, resistance profiles, and local epidemiology, thereby optimizing treatment effectiveness while mitigating adverse effects and the development of antimicrobial resistance. The rapid identification of drug-resistant pathogens through POCT solutions enables early detection of outbreaks and the implementation of infection control measures to curtail further transmission. By facilitating prompt isolation of infected patients, cohorting strategies, and targeted antimicrobial prophylaxis, POCT solutions help mitigate the risk of healthcare-associated infections and contain the spread of antimicrobial resistance.
POCT solutions empower frontline healthcare providers, including physicians, nurses, and pharmacists, to make well-informed treatment decisions at the bedside or in outpatient settings. By integrating antimicrobial resistance surveillance into routine clinical practice, POCT solutions promote antimicrobial stewardship, antibiotic optimization, and evidence-based prescribing practices.
Segmental Insights
Solution Insights
The Diagnostic kits segment is projected to experience rapid growth in the Global Antimicrobial Resistance Surveillance Market during the forecast period. With the global rise in antimicrobial resistance (AMR), there is a growing need for rapid and accurate diagnostic tools to identify drug-resistant pathogens. Diagnostic kits play a crucial role in detecting antimicrobial resistance patterns and guiding appropriate treatment decisions. There is a growing demand for point-of-care testing (POCT) solutions that enable rapid detection of antimicrobial resistance in clinical settings. Diagnostic kits that offer quick and reliable results at the point of care facilitate timely treatment decisions, reduce the spread of drug-resistant infections, and improve patient outcomes. Advances in diagnostic technologies, such as molecular diagnostics, next-generation sequencing, and phenotypic testing methods, have led to the development of innovative diagnostic kits for antimicrobial resistance surveillance. These technologies enhance the speed, sensitivity, and specificity of resistance detection, allowing healthcare providers to tailor treatment regimens based on resistance profiles. Governments and regulatory agencies worldwide are implementing initiatives to address antimicrobial resistance and promote the development and adoption of diagnostic solutions. Regulatory support for innovative diagnostic kits, expedited approval processes, and reimbursement policies incentivize investment in this segment of the market. Healthcare professionals, policymakers, and the public are becoming increasingly aware of the importance of antimicrobial resistance surveillance and the role of diagnostic kits in combating AMR. Educational campaigns, awareness programs, and training initiatives highlight the benefits of early detection and appropriate management of drug-resistant infections.
Regional Insights
North America emerged as the dominant region in the Global Antimicrobial Resistance Surveillance Market in 2023. North America boasts advanced healthcare infrastructure, including well-established surveillance systems and sophisticated laboratory facilities. These resources enable comprehensive monitoring and analysis of antimicrobial resistance patterns. The region is home to numerous pharmaceutical and biotechnology companies that are actively engaged in research and development activities related to antimicrobial resistance surveillance. Investments in innovative technologies and collaborations with academic institutions contribute to the advancement of surveillance capabilities. North America has stringent regulatory frameworks governing antimicrobial resistance surveillance, which promote adherence to standardized methods and protocols. Regulatory agencies such as the Centers for Disease Control and Prevention (CDC) in the United States play a key role in coordinating surveillance efforts and disseminating critical information to healthcare providers and policymakers. There is a high level of awareness among healthcare professionals, policymakers, and the public about the threats posed by antimicrobial resistance in North America. Consequently, there is strong political will to allocate funding and resources toward surveillance initiatives aimed at combating drug-resistant pathogens.
Key Market Players
In this report, the Global Antimicrobial Resistance Surveillance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Antimicrobial Resistance Surveillance Market.
Available Customizations:
Global Antimicrobial Resistance Surveillance market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Testing procedures are governed by standardized protocols and interpretive criteria established by clinical and laboratory standards organizations. Analysis of surveillance data reveals trends in antimicrobial resistance, including changes over time, regional differences, and variations across patient demographics and healthcare settings. Surveillance networks facilitate data sharing, collaboration, and information exchange among healthcare facilities, public health agencies, research institutions, and international organizations. They promote methodological standardization, consistent data reporting, and coordinated responses to combat antimicrobial resistance globally.
Advancements in diagnostic technologies such as molecular diagnostics, next-generation sequencing, and rapid point-of-care testing have transformed antimicrobial resistance surveillance, enabling rapid detection, characterization, and monitoring of drug-resistant pathogens. Antimicrobial stewardship programs have become increasingly important in healthcare facilities to encourage prudent antibiotic use and mitigate the spread of resistant infections. With globalization facilitating the rapid spread of drug-resistant strains, surveillance systems are crucial for monitoring resistance trends, detecting outbreaks, and implementing infection control measures to prevent international transmission.
Key Market Drivers
Technological Advancements in Surveillance Tools
NGS technologies enable rapid and high-throughput sequencing of microbial genomes, facilitating the identification of genetic mutations associated with antimicrobial resistance. NGS allows researchers to analyze entire microbial populations and track the spread of resistant strains with high precision. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), enable the rapid detection of specific genetic markers associated with antimicrobial resistance. These techniques provide accurate and timely information about resistance profiles, guiding treatment decisions and infection control measures. Bioinformatics tools and data analytics platforms enable the analysis and interpretation of large-scale genomic data generated by surveillance efforts. Advanced algorithms and computational techniques facilitate the identification of resistance patterns, genetic determinants, and evolutionary pathways of drug-resistant pathogens. Point-of-Care Testing (POCT) devices allow for rapid and on-site detection of antimicrobial resistance in clinical settings, enabling timely treatment decisions and reducing the spread of drug-resistant infections. POCT technologies leverage miniaturized platforms, microfluidics, and integrated sensors to provide real-time results with minimal sample processing.
Whole Genome Sequencing (WGS) technologies provide comprehensive insights into the genetic composition of microbial populations, including antimicrobial resistance genes, virulence factors, and genomic variations. WGS enables detailed molecular characterization of pathogens and facilitates epidemiological investigations, outbreak detection, and surveillance of resistance trends. Mass spectrometry-based methods, such as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, enable rapid and accurate identification of microbial species and determination of antimicrobial susceptibility profiles. Mass spectrometry platforms offer high throughput and multiplexing capabilities, making them suitable for large-scale surveillance studies. Biosensors and microfluidic devices enable the detection of antimicrobial resistance markers in complex biological samples with high sensitivity and specificity. These miniaturized platforms integrate sensing elements, microfluidic channels, and signal processing components to provide rapid and portable solutions for surveillance applications. This factor will help in the development of the Global Antimicrobial Resistance Surveillance Market.
Growing Need for Antimicrobial Stewardship Programs
Antimicrobial stewardship programs are essential in combating the rising threat of antimicrobial resistance. Surveillance of antimicrobial resistance patterns provides critical data that informs ASPs about the prevalence and trends of resistant pathogens, enabling healthcare facilities to implement targeted interventions to optimize antibiotic use and prevent the spread of resistant infections. Antimicrobial stewardship programs aim to promote judicious and appropriate use of antibiotics to preserve their effectiveness and minimize the development of resistance. Surveillance data helps ASPs monitor antibiotic prescribing practices, identify areas of overuse or misuse, and implement strategies to improve antibiotic prescribing behaviors among healthcare providers. Antimicrobial resistance surveillance data informs empirical therapy guidelines and treatment algorithms by providing insights into local resistance patterns and susceptibility profiles of common pathogens. ASPs use surveillance data to guide the selection of appropriate antibiotics for initial empiric therapy, reducing the risk of treatment failure and the emergence of resistance.
Surveillance of antimicrobial resistance facilitates early detection of outbreaks and emerging resistance trends within healthcare settings and communities. ASPs rely on surveillance data to identify clusters of resistant infections, investigate potential sources of transmission, and implement infection control measures to contain the spread of resistant pathogens. Antimicrobial stewardship programs continuously evaluate the impact of interventions on antibiotic prescribing practices and antimicrobial resistance patterns. Surveillance data allows ASPs to assess the effectiveness of stewardship initiatives, monitor changes in resistance trends over time, and adjust strategies as needed to optimize patient outcomes and minimize the spread of resistance. Many regulatory agencies and accreditation bodies require healthcare facilities to implement antimicrobial stewardship programs as part of efforts to address antimicrobial resistance. Compliance with regulatory requirements necessitates the implementation of robust surveillance systems to monitor antimicrobial use and resistance patterns, driving demand for surveillance solutions in the market. This factor will pace up the demand of the Global Antimicrobial Resistance Surveillance Market.
Emerging Infectious Diseases and Pandemics
During outbreaks of emerging infectious diseases or pandemics, there is often a surge in antibiotic use, both for treating bacterial co-infections and as a precautionary measure. This overuse of antibiotics can contribute to the development and spread of antimicrobial resistance among pathogens, exacerbating the AMR crisis. Emerging infectious diseases and pandemics can complicate treatment protocols by introducing new pathogens or strains with unique resistance profiles. Surveillance of antimicrobial resistance patterns becomes essential for understanding the susceptibility of these pathogens to available antibiotics and guiding treatment decisions. Antimicrobial resistance surveillance helps in the early detection of drug-resistant strains of pathogens associated with emerging infectious diseases and pandemics. Timely identification of resistant strains enables healthcare authorities to implement appropriate infection control measures, prevent further transmission, and optimize treatment strategies to improve patient outcomes.
Surveillance of antimicrobial resistance provides valuable data on the dynamics of resistance development and spread during outbreaks and pandemics. Understanding the patterns of resistance evolution helps public health agencies and healthcare providers anticipate future challenges, adapt treatment protocols, and develop targeted interventions to mitigate the impact of AMR. Effective surveillance of antimicrobial resistance is crucial for preserving the efficacy of antibiotics and other antimicrobial agents used to treat both common and emerging infectious diseases. By monitoring resistance trends and patterns, healthcare systems can implement antimicrobial stewardship programs and infection prevention measures to minimize the selective pressure driving resistance evolution. Emerging infectious diseases and pandemics require coordinated global efforts to monitor, control, and mitigate their impact. Antimicrobial resistance surveillance fosters collaboration among countries, international organizations, and research institutions to share data, resources, and best practices for responding to public health emergencies effectively. This factor will accelerate the demand of the Global Antimicrobial Resistance Surveillance Market.
Key Market Challenges
Rapidly Evolving Resistance Patterns
Pathogens can develop resistance to antimicrobial agents through various mechanisms, including genetic mutations, horizontal gene transfer, and the acquisition of mobile genetic elements. The diverse and evolving nature of resistance mechanisms makes it challenging to predict and track changes in resistance patterns accurately. New and unexpected resistance mechanisms can emerge over time, rendering existing surveillance methods and assays ineffective in detecting and characterizing resistant strains. The identification of novel resistance mechanisms requires continuous research and development efforts to update surveillance tools and technologies accordingly. Drug-resistant pathogens can spread rapidly within and across healthcare settings, communities, and geographic regions. The global dissemination of resistant strains complicates surveillance efforts and necessitates international collaboration and data sharing to monitor resistance trends and prevent the spread of resistant infections. The selective pressure exerted by the widespread use and misuse of antibiotics accelerates the development and spread of antimicrobial resistance. Antibiotic exposure drives the selection of resistant bacterial populations, leading to the emergence of multidrug-resistant strains that are difficult to treat and control. Pathogens have the capacity to adapt and evolve in response to environmental pressures, including exposure to antimicrobial agents. The adaptive evolution of pathogens allows them to develop mechanisms to evade the effects of antibiotics, leading to the persistence and proliferation of resistant strains in clinical and community settings. Resistance patterns can vary widely among different pathogens, patient populations, and geographic locations. The heterogeneity of resistance patterns presents challenges in standardizing surveillance methods, interpreting surveillance data, and implementing targeted interventions to address specific resistance threats effectively.
Lack of Standardization
There is a lack of standardized protocols and methodologies for data collection, analysis, and reporting across different regions, healthcare settings, and surveillance programs. This inconsistency makes it difficult to compare and interpret surveillance data accurately, hindering efforts to monitor antimicrobial resistance trends on a global scale. Variability in testing procedures, including antimicrobial susceptibility testing methods, interpretive criteria, and quality control measures, can lead to discrepancies in resistance data reported by different laboratories and surveillance systems. Without standardized testing protocols, the reliability and comparability of surveillance data are compromised. Surveillance infrastructure varies widely among countries and healthcare systems, resulting in disparities in surveillance capabilities and data quality. Resource-limited settings may lack the necessary laboratory facilities, trained personnel, and data management systems to conduct robust antimicrobial resistance surveillance effectively. The lack of standardized data formats, interoperable systems, and secure platforms for data sharing and integration hinders collaboration and information exchange among stakeholders involved in antimicrobial resistance surveillance. Fragmented data silos impede efforts to track resistance trends, identify emerging threats, and coordinate response strategies across borders and sectors. Differences in definitions, terminologies, and classification schemes used to describe antimicrobial resistance phenotypes and resistance mechanisms can lead to confusion and misinterpretation of surveillance data. Harmonizing terminology and standardizing nomenclature are essential for ensuring consistency and accuracy in resistance surveillance reporting.
Key Market Trends
Point-of-Care Testing (POCT) Solutions
Point-of-care testing (POCT) solutions facilitate swift and on-site detection of antimicrobial resistance in clinical environments, enabling healthcare providers to promptly determine treatment courses. This rapid access to test results expedites the commencement of appropriate antibiotic therapy, leading to enhanced patient outcomes and reduced spread of drug-resistant infections. Unlike conventional laboratory-based antimicrobial susceptibility testing (AST) methods, which often involve lengthy turnaround times, POCT solutions offer near-real-time results, minimizing delays in diagnosis and allowing healthcare providers to promptly select the most effective antibiotics.
POCT solutions support personalized and precision medicine approaches by furnishing actionable insights into antimicrobial resistance patterns and susceptibility profiles. This empowers healthcare providers to customize antibiotic therapy based on individual patient characteristics, resistance profiles, and local epidemiology, thereby optimizing treatment effectiveness while mitigating adverse effects and the development of antimicrobial resistance. The rapid identification of drug-resistant pathogens through POCT solutions enables early detection of outbreaks and the implementation of infection control measures to curtail further transmission. By facilitating prompt isolation of infected patients, cohorting strategies, and targeted antimicrobial prophylaxis, POCT solutions help mitigate the risk of healthcare-associated infections and contain the spread of antimicrobial resistance.
POCT solutions empower frontline healthcare providers, including physicians, nurses, and pharmacists, to make well-informed treatment decisions at the bedside or in outpatient settings. By integrating antimicrobial resistance surveillance into routine clinical practice, POCT solutions promote antimicrobial stewardship, antibiotic optimization, and evidence-based prescribing practices.
Segmental Insights
Solution Insights
The Diagnostic kits segment is projected to experience rapid growth in the Global Antimicrobial Resistance Surveillance Market during the forecast period. With the global rise in antimicrobial resistance (AMR), there is a growing need for rapid and accurate diagnostic tools to identify drug-resistant pathogens. Diagnostic kits play a crucial role in detecting antimicrobial resistance patterns and guiding appropriate treatment decisions. There is a growing demand for point-of-care testing (POCT) solutions that enable rapid detection of antimicrobial resistance in clinical settings. Diagnostic kits that offer quick and reliable results at the point of care facilitate timely treatment decisions, reduce the spread of drug-resistant infections, and improve patient outcomes. Advances in diagnostic technologies, such as molecular diagnostics, next-generation sequencing, and phenotypic testing methods, have led to the development of innovative diagnostic kits for antimicrobial resistance surveillance. These technologies enhance the speed, sensitivity, and specificity of resistance detection, allowing healthcare providers to tailor treatment regimens based on resistance profiles. Governments and regulatory agencies worldwide are implementing initiatives to address antimicrobial resistance and promote the development and adoption of diagnostic solutions. Regulatory support for innovative diagnostic kits, expedited approval processes, and reimbursement policies incentivize investment in this segment of the market. Healthcare professionals, policymakers, and the public are becoming increasingly aware of the importance of antimicrobial resistance surveillance and the role of diagnostic kits in combating AMR. Educational campaigns, awareness programs, and training initiatives highlight the benefits of early detection and appropriate management of drug-resistant infections.
Regional Insights
North America emerged as the dominant region in the Global Antimicrobial Resistance Surveillance Market in 2023. North America boasts advanced healthcare infrastructure, including well-established surveillance systems and sophisticated laboratory facilities. These resources enable comprehensive monitoring and analysis of antimicrobial resistance patterns. The region is home to numerous pharmaceutical and biotechnology companies that are actively engaged in research and development activities related to antimicrobial resistance surveillance. Investments in innovative technologies and collaborations with academic institutions contribute to the advancement of surveillance capabilities. North America has stringent regulatory frameworks governing antimicrobial resistance surveillance, which promote adherence to standardized methods and protocols. Regulatory agencies such as the Centers for Disease Control and Prevention (CDC) in the United States play a key role in coordinating surveillance efforts and disseminating critical information to healthcare providers and policymakers. There is a high level of awareness among healthcare professionals, policymakers, and the public about the threats posed by antimicrobial resistance in North America. Consequently, there is strong political will to allocate funding and resources toward surveillance initiatives aimed at combating drug-resistant pathogens.
Key Market Players
- Luminex Corporation (DiaSorin)
- Thermo Fisher Scientific Inc
- Accelerate Diagnostics, Inc.
- Liofilchem S.r.I.
- Becton, Dickinson, and Company
- Biomerieux Inc.
- Bruker Corp.
- Danaher Corporation
- Merck KgaA
- Abbott Laboratories Inc.
In this report, the Global Antimicrobial Resistance Surveillance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Antimicrobial Resistance Surveillance Market, By Solution:
- Diagnostic kits
- Diagnostic systems
- Surveillance software
- Services
- Antimicrobial Resistance Surveillance Market, By Application:
- Clinical Diagnostics
- Public Health Surveillance
- Other Applications
- Antimicrobial Resistance Surveillance Market, By End User:
- Hospitals & Clinics
- Research & Academic Institutes
- Others
- Antimicrobial Resistance Surveillance Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies presents in the Global Antimicrobial Resistance Surveillance Market.
Available Customizations:
Global Antimicrobial Resistance Surveillance market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services)
5.2.2. By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications)
5.2.3. By End User (Hospitals & Clinics, Research & Academic Institutes, Others)
5.2.4. By Region
5.2.5. By Company (2023)
5.3. Market Map
6. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Solution
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Antimicrobial Resistance Surveillance Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Solution
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Antimicrobial Resistance Surveillance Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Solution
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Antimicrobial Resistance Surveillance Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Solution
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Solution
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Antimicrobial Resistance Surveillance Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Solution
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. United Kingdom Antimicrobial Resistance Surveillance Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Solution
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. Italy Antimicrobial Resistance Surveillance Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Solution
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. France Antimicrobial Resistance Surveillance Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Solution
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Spain Antimicrobial Resistance Surveillance Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Solution
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Solution
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Antimicrobial Resistance Surveillance Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Solution
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. India Antimicrobial Resistance Surveillance Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Solution
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. Japan Antimicrobial Resistance Surveillance Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Solution
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Antimicrobial Resistance Surveillance Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Solution
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Antimicrobial Resistance Surveillance Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Solution
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. SOUTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Solution
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Antimicrobial Resistance Surveillance Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Solution
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Argentina Antimicrobial Resistance Surveillance Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Solution
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Colombia Antimicrobial Resistance Surveillance Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Solution
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. MIDDLE EAST AND AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Solution
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Antimicrobial Resistance Surveillance Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Solution
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Antimicrobial Resistance Surveillance Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Solution
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. UAE Antimicrobial Resistance Surveillance Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Solution
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Luminex Corporation (DiaSorin)
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Thermo Fisher Scientific Inc
14.3. Accelerate Diagnostics, Inc.
14.4. Liofilchem S.r.I.
14.5. Becton, Dickinson and Company
14.6. Biomerieux Inc.
14.7. Bruker Corp.
14.8. Danaher Corporation
14.9. Merck KgaA
14.10.Abbott Laboratories Inc.
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services)
5.2.2. By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications)
5.2.3. By End User (Hospitals & Clinics, Research & Academic Institutes, Others)
5.2.4. By Region
5.2.5. By Company (2023)
5.3. Market Map
6. NORTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Solution
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Antimicrobial Resistance Surveillance Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Solution
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Antimicrobial Resistance Surveillance Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Solution
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Antimicrobial Resistance Surveillance Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Solution
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. EUROPE ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Solution
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Antimicrobial Resistance Surveillance Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Solution
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. United Kingdom Antimicrobial Resistance Surveillance Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Solution
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. Italy Antimicrobial Resistance Surveillance Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Solution
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. France Antimicrobial Resistance Surveillance Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Solution
7.3.4.2.2. By Application
7.3.4.2.3. By End User
7.3.5. Spain Antimicrobial Resistance Surveillance Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Solution
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Solution
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Antimicrobial Resistance Surveillance Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Solution
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. India Antimicrobial Resistance Surveillance Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Solution
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. Japan Antimicrobial Resistance Surveillance Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Solution
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Antimicrobial Resistance Surveillance Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Solution
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Antimicrobial Resistance Surveillance Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Solution
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. SOUTH AMERICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Solution
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Antimicrobial Resistance Surveillance Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Solution
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Argentina Antimicrobial Resistance Surveillance Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Solution
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Colombia Antimicrobial Resistance Surveillance Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Solution
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. MIDDLE EAST AND AFRICA ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Solution
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Antimicrobial Resistance Surveillance Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Solution
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Antimicrobial Resistance Surveillance Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Solution
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. UAE Antimicrobial Resistance Surveillance Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Solution
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. COMPETITIVE LANDSCAPE
14.1. Luminex Corporation (DiaSorin)
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Thermo Fisher Scientific Inc
14.3. Accelerate Diagnostics, Inc.
14.4. Liofilchem S.r.I.
14.5. Becton, Dickinson and Company
14.6. Biomerieux Inc.
14.7. Bruker Corp.
14.8. Danaher Corporation
14.9. Merck KgaA
14.10.Abbott Laboratories Inc.
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
